BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Imatinib mesylate prodrug (IkT-001Pro) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Imatinib mesylate prodrug (IkT-001Pro)\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07365332-538@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Imatinib mesylate prodrug (IkT-001Pro): Phase 3 readout est. (NCT07
 365332)
DESCRIPTION:Imatinib mesylate prodrug (IkT-001Pro)\, phase 3\, Pulmonary Ar
 terial Hypertension.\nStudy: An Adaptive Program of IKT-001 in Pulmonary A
 rterial Hypertension (PAH)\nEstimated primary completion: June 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/imatinib-mesylate-prodrug-
 ikt-001pro#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07365332
URL:https://assetmemo.bio/drug/imatinib-mesylate-prodrug-ikt-001pro#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07632898-538@assetmemo.bio
DTSTAMP:20261121T010021Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Imatinib mesylate prodrug (IkT-001Pro): Phase 3 readout est. (NCT07
 632898)
DESCRIPTION:Imatinib mesylate prodrug (IkT-001Pro)\, phase 3\, Pulmonary Ar
 terial Hypertension.\nStudy: Open-Label Study of IKT-001 in Pulmonary Arte
 rial Hypertension (PAH)\nEstimated primary completion: 30 June 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/imatinib-mesylate-prodrug-
 ikt-001pro#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07632898
URL:https://assetmemo.bio/drug/imatinib-mesylate-prodrug-ikt-001pro#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
